Home » GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES

GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES

June 5, 2006

GlaxoSmithKline Plc has signed a deal to licence in a substantial portfolio of tumour-specific antigens from the international Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.
The Scotsman

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

12Feb
Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...
17Mar
FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers
19Mar
SOPs and Policies for the 21st Century: Why Less is More
20Apr
17th Annual Medical Device Quality Congress

New!

17th Medical Device Quality Congress

Learn More Here

GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES

Upcoming Events

Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

SOPs and Policies for the 21st Century: Why Less is More

17th Annual Medical Device Quality Congress

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

FDA Approves Abbott’s Heart Pump in Surgical Procedure

FDA Fires Back at Study Critiquing Opioid REMS Strategy

Medtronic Nabs CE Mark for Neurostimulator

Pharmacies in Opioid MDL Must Turn Over 14 Years of Opioid Data

New!

17th Medical Device Quality Congress